Ovarian cancer, a deadly gynecological disease, continues to pose a significant challenge, with an estimated 19,680 new cases and 12,740 deaths projected for 2024. The standard treatment involves primary surgery followed by chemotherapy, but achieving optimal results can be tricky, especially in advanced stages or poor medical conditions. This is where alternative strategies like neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) come into play.
When primary debulking surgery isn't feasible or attempted, a biopsy is performed for diagnosis, followed by NAC. After a few cycles and responses, secondary surgery or interval debulking surgery (IDS) may become an option. Despite advancements in treatment and surgical techniques, achieving optimal cytoreduction remains a hurdle for improved survival in ovarian cancer patients.
Traditional laparotomy IDS after NAC has shown benefits, but a shorter recovery and complete cytoreduction are still challenging due to tumor burden, surgical complexity, and varying expertise. This is where robotic-assisted surgery steps in, offering the potential to enhance precision, reduce complications, and improve optimal debulking rates in interval surgery. However, its effectiveness compared to conventional methods is still unclear.
Previous meta-analyses have explored the benefits of robotic surgery in ovarian cancer, but this study specifically compares robotic interval debulking surgery and laparotomy. The aim is to evaluate the role of robotic-assisted surgery in interval debulking and its impact on surgical outcomes, including complete cytoreduction, operative time, blood loss, hospital stay, and complications.
This systematic review follows the guidelines recommended by the Cochrane Group and the PRISMA 2020 statement. A thorough search strategy was employed, and the studies included were observational, focusing on the outcome of robotic interval debulking surgery on ovarian cancer patients (FIGO stage I-IV) compared to laparotomy. Only studies published within the last ten years were considered.
The results showed that robotic interval debulking surgery (R-IDS) offers significant advantages, especially in advanced-stage and recurrent ovarian cancer. It improves complete cytoreduction rates, reduces blood loss, and shortens hospital stays. These benefits are attributed to enhanced surgical precision, 3D visualization, and superior instrument control. Recent advancements in minimally invasive technology further support this approach.
Despite these advantages, many patients are unaware of the potential benefits of robotic-assisted surgery. Studies indicate that 75% of patients are eligible for robotic IDS, highlighting its feasibility as an alternative to conventional laparotomy in select cases. The challenge lies in achieving optimal debulking in advanced and recurrent ovarian cancer, especially in cases with extensive disease involvement, which can be complex and risky.
Our meta-analysis, supported by previous studies, reveals that robotic IDS is associated with significantly reduced estimated blood loss and hospital stay. The majority of debulking surgeries achieved 80% complete cytoreduction, with a higher proportion in patients undergoing robotic IDS compared to laparotomy. Additionally, robotic IDS has a longer operative time due to the complexity and precision required.
However, we were unable to provide comprehensive prognostic factors, such as progression-free and overall survival, due to limited data. One study reported an overall survival of 42.8 months in the robotic IDS group compared to 37.9 months in the laparotomy group. These findings should be interpreted cautiously, considering the presence of microscopic residual disease (MRD), which can influence long-term prognosis regardless of the surgical approach.
Robot-assisted interval surgery has significant clinical implications. By improving surgical precision and visualization, it can enhance the completeness of cytoreduction, a critical factor in survival outcomes for advanced and recurrent ovarian cancer. Reduced surgical trauma may also lead to less blood loss and shorter hospital stays. If validated through clinical trials, robot-assisted interval debulking surgery could become a new standard of care, bridging the gap between maximal cytoreduction and minimally invasive robotic approaches, and ultimately improving outcomes for women with ovarian cancer.
This study is the first meta-analysis comparing robotic interval debulking surgery and laparotomy in ovarian cancer. The bias risk associated with each included study was low, indicating the quality of the studies. However, there are limitations, including diverse sample sizes and a focus on America, Europe, and Asia, suggesting that this research is still uncommon in middle- and lower-income countries. The number of included studies was limited, and follow-up profiles were reported in only one study, restricting the variables that could be analyzed.
In conclusion, robotic-assisted interval debulking surgery shows promising surgical outcomes for women with recurrent and advanced-stage ovarian cancer. The small number of included studies and moderate risk of bias in follow-up cohort parameters should be considered when interpreting the findings. Further research is needed to validate these results and expand our understanding of this innovative approach.
